Overview
Clinical-stage biotech developing subcutaneous ketamine formulations and wearable delivery devices for psychiatric treatment outside traditional clinic settings. Their approach aims to make ketamine therapy more accessible and scalable.
More in Psychedelics
Latest industry news
BlueWind Medical's Revi Extend Wins FDA Clearance, Extending Implant Life to 15 Years
2026-08-06 · Product
Neurofeedback Systems Market Eyes $2.95 Billion Valuation by 2035 as Clinical and Consumer Demand Converge
2026-08-05 · Industry
Smaller Neuromodulation Devices Are Reshaping the Competitive Landscape for TMS Providers
2026-08-04 · Industry
NIH-Backed Brain-Computer Device Restores Speech in Paralyzed Patient
2026-08-03 · Research
Company details
Category
🍄 Psychedelics
Location
Nevada City, CA, USA
Funding
Seed · $5M
Website
bexsonbiomedical.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →